JPH07505714A - 流体試料中のチロキシンを検出・定量するための試薬および方法 - Google Patents
流体試料中のチロキシンを検出・定量するための試薬および方法Info
- Publication number
- JPH07505714A JPH07505714A JP5517596A JP51759693A JPH07505714A JP H07505714 A JPH07505714 A JP H07505714A JP 5517596 A JP5517596 A JP 5517596A JP 51759693 A JP51759693 A JP 51759693A JP H07505714 A JPH07505714 A JP H07505714A
- Authority
- JP
- Japan
- Prior art keywords
- thyroxine
- moiety
- heteroatoms
- group
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 title claims description 137
- 229940034208 thyroxine Drugs 0.000 title claims description 108
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 title claims description 105
- 238000000034 method Methods 0.000 title claims description 99
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 79
- 239000012530 fluid Substances 0.000 title description 2
- 230000002163 immunogen Effects 0.000 claims description 75
- 125000005842 heteroatom Chemical group 0.000 claims description 50
- 239000000700 radioactive tracer Substances 0.000 claims description 46
- 238000009739 binding Methods 0.000 claims description 43
- 238000002372 labelling Methods 0.000 claims description 40
- 238000012360 testing method Methods 0.000 claims description 38
- 239000000126 substance Substances 0.000 claims description 35
- 125000004432 carbon atom Chemical group C* 0.000 claims description 30
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 28
- 125000004122 cyclic group Chemical group 0.000 claims description 28
- 238000003018 immunoassay Methods 0.000 claims description 28
- 210000002966 serum Anatomy 0.000 claims description 27
- 229940098773 bovine serum albumin Drugs 0.000 claims description 25
- 238000002875 fluorescence polarization Methods 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 239000012876 carrier material Substances 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 229920006395 saturated elastomer Polymers 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 14
- 229950008325 levothyroxine Drugs 0.000 claims description 13
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical group IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 8
- 238000011088 calibration curve Methods 0.000 claims description 8
- 125000005647 linker group Chemical group 0.000 claims description 8
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 8
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 102000009843 Thyroglobulin Human genes 0.000 claims description 6
- 108010034949 Thyroglobulin Proteins 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 230000001588 bifunctional effect Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940027941 immunoglobulin g Drugs 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 229960002175 thyroglobulin Drugs 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- -1 cetyl-thyroxine Chemical compound 0.000 claims description 5
- 230000009260 cross reactivity Effects 0.000 claims description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- XJFBYWMUHDQLCZ-INIZCTEOSA-N (2s)-2-[tert-butyl(carboxymethyl)amino]-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid Chemical compound IC1=CC(C[C@H](N(CC(O)=O)C(C)(C)C)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XJFBYWMUHDQLCZ-INIZCTEOSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 3
- 238000002967 competitive immunoassay Methods 0.000 claims description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 claims description 3
- 125000004494 ethyl ester group Chemical group 0.000 claims description 3
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 claims description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 108060003552 hemocyanin Proteins 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 claims description 2
- 238000000711 polarimetry Methods 0.000 claims description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 4
- 102000001554 Hemoglobins Human genes 0.000 claims 3
- 108010054147 Hemoglobins Proteins 0.000 claims 3
- 238000006640 acetylation reaction Methods 0.000 claims 3
- GXMFSGFJPBLQKT-KRWDZBQOSA-N acetyl (2s)-2-(tert-butylamino)-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate Chemical compound IC1=CC(C[C@@H](C(=O)OC(=O)C)NC(C)(C)C)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 GXMFSGFJPBLQKT-KRWDZBQOSA-N 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 229940035722 triiodothyronine Drugs 0.000 claims 2
- 101710153593 Albumin A Proteins 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- NTPYDYPGKBRFFP-FQEVSTJZSA-N acetyl (2s)-2-[tert-butyl-(2-ethoxy-2-oxoethyl)amino]-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate Chemical compound IC1=CC(C[C@H](N(CC(=O)OCC)C(C)(C)C)C(=O)OC(C)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 NTPYDYPGKBRFFP-FQEVSTJZSA-N 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 238000006473 carboxylation reaction Methods 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 210000000087 hemolymph Anatomy 0.000 claims 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical group [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000000691 measurement method Methods 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 238000005259 measurement Methods 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 125000000524 functional group Chemical group 0.000 description 12
- NERGVJCCFAPEMR-AWEZNQCLSA-N (2s)-2-acetamido-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid Chemical compound IC1=CC(C[C@H](NC(=O)C)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 NERGVJCCFAPEMR-AWEZNQCLSA-N 0.000 description 11
- 238000011002 quantification Methods 0.000 description 11
- 230000010287 polarization Effects 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 102000014914 Carrier Proteins Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000003127 radioimmunoassay Methods 0.000 description 7
- 125000006850 spacer group Chemical group 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000008094 contradictory effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000270281 Coluber constrictor Species 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 102000009488 Thyroxine-Binding Proteins Human genes 0.000 description 3
- 108010048889 Thyroxine-Binding Proteins Proteins 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- LKKOOHKPOMOOAI-UHFFFAOYSA-N [3-fluoro-4-(trifluoromethoxy)phenyl]methanamine Chemical compound NCC1=CC=C(OC(F)(F)F)C(F)=C1 LKKOOHKPOMOOAI-UHFFFAOYSA-N 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- OQZCSNDVOWYALR-UHFFFAOYSA-N flurochloridone Chemical compound FC(F)(F)C1=CC=CC(N2C(C(Cl)C(CCl)C2)=O)=C1 OQZCSNDVOWYALR-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000004071 soot Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102400000096 Substance P Human genes 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 2
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229960001767 dextrothyroxine Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- VSWSDTLXDWESGZ-AWEZNQCLSA-N (2s)-3-[4-(4-hydroxyphenoxy)phenyl]-2-(iodoamino)propanoic acid Chemical group C1=CC(C[C@@H](C(=O)O)NI)=CC=C1OC1=CC=C(O)C=C1 VSWSDTLXDWESGZ-AWEZNQCLSA-N 0.000 description 1
- LJJFNFYPZOHRHM-UHFFFAOYSA-N 1-isocyano-2-methoxy-2-methylpropane Chemical compound COC(C)(C)C[N+]#[C-] LJJFNFYPZOHRHM-UHFFFAOYSA-N 0.000 description 1
- PCLIRWBVOVZTOK-UHFFFAOYSA-M 2-(1-methylpyrrolidin-1-ium-1-yl)ethyl 2-hydroxy-2,2-diphenylacetate;iodide Chemical compound [I-].C=1C=CC=CC=1C(O)(C=1C=CC=CC=1)C(=O)OCC[N+]1(C)CCCC1 PCLIRWBVOVZTOK-UHFFFAOYSA-M 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- YOAWSYSKQHLFPM-UHFFFAOYSA-N 5-amino-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(N)C=C21 YOAWSYSKQHLFPM-UHFFFAOYSA-N 0.000 description 1
- GZAJOEGTZDUSKS-UHFFFAOYSA-N 5-aminofluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(N)=CC=C21 GZAJOEGTZDUSKS-UHFFFAOYSA-N 0.000 description 1
- HTPXFGUCAUTOEL-UHFFFAOYSA-N 9h-fluorene-1-carboxylic acid Chemical class C1C2=CC=CC=C2C2=C1C(C(=O)O)=CC=C2 HTPXFGUCAUTOEL-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020740 Hyperproteinaemia Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 101710097943 Viral-enhancing factor Proteins 0.000 description 1
- YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 1
- GQQLGSQRXPUASB-UHFFFAOYSA-L [Na+].[Na+].[O-]C([O-])=O.CN(C)C=O Chemical compound [Na+].[Na+].[O-]C([O-])=O.CN(C)C=O GQQLGSQRXPUASB-UHFFFAOYSA-L 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- BJFIGCBESRQZMQ-UHFFFAOYSA-N formic acid;1h-imidazole Chemical class OC=O.C1=CNC=N1 BJFIGCBESRQZMQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000002420 orchard Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/807—Hapten conjugated with peptide or protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (56)
- (1)テスト試料中のチロキシンを定量するための競合的免疫測定法において、 下記工程: (a)テスト試料を、チロキシンおよび下記式:▲数式、化学式、表等がありま す▼ [式中、Qは検出可能部分であり、Wは結合部分である。]の標識化試薬に結合 可能な抗体を含む抗体試薬と接触させる工程、および (b)反応溶液中の該抗体と結合した標識化試薬の量をテスト試料中のチロキシ ンの量の関数として測定する工程を含むことを特徴とする方法。
- (2)Wが直鎖もしくは分岐鎖、または環式あるいはそれらの組み合わせで配列 した、飽和または不飽和の、0〜50個の炭素原子およびヘテロ原子(ヘテロ原 子は10個以下)から成るが、ただし、1)ヘテロ原子が直接結合するのは2個 までであり、2)Wは−O−O−結合を含むことができず、3)環式部分は6員 環か、それより小さく、4)分岐は炭素原子上にのみあることを特徴とする請求 項1に記載の方法。
- (3)ヘテロ原子が、窒素、酸素、硫黄およびリンから成る群から選択されるこ とを特徴とする請求項2に記載の方法。
- (4)検出可能な部分が、酸素、発色団、蛍光性分子、化学発光性分子、燐光性 分子および発光性分子から成る群から選択されることを特徴とする請求項1に記 載の方法。
- (5)抗体を、下記式: ▲数式、化学式、表等があります▼ [式中、(a)Pは免疫原担体物質であり、Xは第二結合部分であり、(b)P のチロキシン誘導体による置換度は1〜100%である。]の化合物から得られ る免疫原により産生することを特徴とする請求項1に記載の方法。
- (6)Xが直鎖もしくは分岐鎖、または環式あるいはそれらの組み合わせで配列 した、飽和または不飽和の、0〜50個の炭素原子およびヘテロ原子(ヘテロ原 子は10個以下)から成るが、ただし、1)ヘテロ原子が直接結合するのは2個 までであり、2)Xは−O−O−結合を含むことができず、3)環式部分は6員 環か、それより小さく、4)分岐は炭素原子上にのみあることを特徴とする請求 項5に記載の方法。
- (7)Wが直鎖もしくは分岐鎖、または環式あるいはそれらの組み合わせで配列 した、飽和または不飽和の、0〜50個の炭素原子およびヘテロ原子(ヘテロ原 子は10個以下)から成るが、ただし、1)ヘテロ原子が直接結合するのは2個 までであり、2)Wは−O−O−結合を含むことができず、3)環式部分は6員 環か、それより小さく、4)分岐は炭素原子上にのみあることを特徴とする請求 項6に記載の方法。
- (8)免疫原担体物質が牛血清アルブミン(BSA)、keyhole lim petヘモシアニンおよびチログロブリンから成る群から選択されることを特徴 とする請求項5に記載の方法。
- (9)免疫測定法が蛍光偏光イムノアッセイであり、標識化試薬の検出可能な部 分が蛍光性部分であることを特徴とする請求項1に記載の方法。
- (10)Wが直鎖もしくは分岐鎖、または環式あるいはそれらの組み合わせで配 列した、飽和または不飽和の、0〜50個の炭素原子およびヘテロ原子(ヘテロ 原子は10個以下)から成るが、ただし、1)ヘテロ原子が直接結合するのは2 個までであり、2)Wは−O−O−結合を含むことができず、3)環式部分は6 員環か、それより小さく、4)分岐は炭素原子上にのみあることを特徴とする請 求項9に記載の方法。
- (11)抗体を、下記式: ▲数式、化学式、表等があります▼ [式中、(a)Pは免疫原担体物質であり、(b)Xは第二結合部分であり、( c)Pのチロキシン誘導体による置換度は1〜100%である。]の免疫原によ り産生することを特徴とする請求項9に記載の方法。
- (12)Xが直鎖もしくは分岐鎖、または環式あるいはそれらの組み合わせで配 列した、飽和または不飽和の、0〜50個の炭素原子およびヘテロ原子(ヘテロ 原子は10個以下)から成るが、ただし、1)ヘテロ原子が直接結合するのは2 個までであり・2)Xは−O−O−結合を含むことができず、3)環式部分は6 員環か、それより小さく、4)分岐は炭素原子上にのみあることを特徴とする請 求項11に記載の方法。
- (13)Wが直鎖もしくは分岐鎖、または環式あるいはそれらの組み合わせて配 列した、飽和または不飽和の、0〜50個の炭素原子およびヘテロ原子(ヘテロ 原子は10個以下)から成るが、ただし、1)ヘテロ原子が直接結合するのは2 個までであり、2)Wは−O−O−結合を含むことができず、3)環式部分は6 員環か、それより小さく、4)分岐は炭素原子上にのみあるこどを特徴とする請 求項12に記載の方法。
- (14)免疫原担体物質が牛血清アルブミン、keyholelimpetヘモ シアニンおよびチログロブリンから成る群がら選択されることを特徴とする請求 項10に記載の方法。
- (15)標識化試薬の量を、(a)平面偏光を反応溶液に通して蛍光偏光応答を 生じさせ、(b)該反応溶液の蛍光偏光応答をテスト試料中のチロキシンの関数 として検出する、ことにより測定することを特徴とする請求項9に記載の方法。
- (16)蛍光性分子が、アミノメチルフルオレセン、アミノフルオレセン、5− カルボキシフルオレセン、6−カルボキシフルオレセン、チオウレアフルオレセ ンおよびメトキシトリアジノリルーアミノフルオレセンから成る群から選択され ることを特徴とする請求項9に記載の方法。
- (17)イムノアッセイの結果をミリ偏光単位(mP)で表し、このmP単位を 標準検量線と対比して試料中のチロキシン濃度として表し、標準検量線の最小偏 光範囲が少なくとも100mPであることを特徴とする請求項15に記載の方法 。
- (18)イムノアッセイにより試料中の0〜24mg/dlのチロキシンが検出 可能であることを特徴とする請求項15に記載の方法。
- (19)抗体と試料中のトリヨードチロニンとの交差反応が約15%以下であり 、標識化試薬が試料中の内在性免疫グロブリンGと結合しないことを特徴とする 請求項11に記載の方法。
- (20)イムノァッセイの結果をミリ偏光単位(mP)で表し、このmP単位を 標準検量線と対比して試料中のチロキシン濃度として表し、標準検量線の最小偏 光範囲が少なくとも100mPであり、試料中の0〜24mg/dlのチロキシ ンが検出可能であることを特徴とする請求項19に記載の方法。
- (21)標識化試薬が下記式: ▲数式、化学式、表等があります▼ であり、抗体が下記式: ▲数式、化学式、表等があります▼ [式中、BSAは牛血清アルブミンを示し、BSAのチロキシン誘導体による置 換度は1〜100%である。]の免疫源により得られることを特徴とする請求項 1に記載の方法。
- (22)下記式: ▲数式、化学式、表等があります▼ [式中、(a)Pは免疫原担体物質であり、(b)Xは結合部分であり、(c) Pのチロキシン誘導体による置換度は1〜100%である。]の免疫原により産 生される抗体。
- (23)Xが直鎖もしくは分岐鎖、または環式あるいはそれらの組み合わせで配 列した、飽和または不飽和の、0〜50個の炭素原子およびヘテロ原子(ヘテロ 原子は10個以下)から成るが、ただし、1)ヘテロ原子が直接結合するのは2 値までであり、2)Xは−O−O−結合を含むことができず、3)環式部分は6 員環か、それより小さく、4)分岐は炭素原子上にのみあることを特徴とする請 求項22に記載の抗体。
- (24)免疫原担体物質が牛血清アルブミン、keyholelimpetヘモ シアニンおよびチログロブリンから成る群がら選択されることを特徴とする請求 項23に記載の抗体。
- (25)下記式: ▲数式、化学式、表等があります▼ [式中、BSAは牛血清アルブミンを示し、BSAのチロキシン誘導体による置 換度は1〜100%である。]の免疫原により得られる抗体。
- (26)チロキシンおよびトレーサーの両方に結合可能な抗体であって、トレー サーとの結合が気競合的にチロキシンと置き代わることが可能であり、該トレー サーが下記式:▲数式、化学式、表等があります▼ を有し、該抗体がチロキシンの蛍光偏光測定法において該トレーサーとともに使 用することができる抗体。
- (27)さらに、抗体とトリヨードチロニンとの交差反応性が15%未満である ことを特徴とする請求項26に記載の抗体。
- (28)チロキシンがL−チロキシンであり、式で示した化合物がL−異性体で あることを特徴とする請求項26に記載の抗体。
- (29)モノクローナル抗体1−189−252。
- (30)ATCC寄託番号がHB11125である細胞系。
- (31)下記式: ▲数式、化学式、表等があります▼ [式中、Qは検出可能な部分であり、Wは結合部分である。]の標識化試薬。
- (32)Wが直鎖もしくは分岐鎖、または環式あるいはそれらの組み合わせで配 列した、飽和または不飽和の、0〜50個の炭素原子およびヘテロ原子(ヘテロ 原子は10個以下)から成るが、ただし、1)ヘテロ原子が直接結合するのは2 個までであり、2)Wは−O−O−結合を含むことができず、3)環式部分は6 員環か、それより小さく、4)分岐は炭素原子上にのみあることを特徴とする請 求項31に記載の標識化試薬。
- (33)検出可能な部分が、酵素、発色団、蛍光性分子、化学発光性分子、燐光 性分子および発光性分子から成る群から選択されることを特徴とする請求項31 に記載の標識化試薬。
- (34)蛍光性分子が、アミノメチルフルオレセン、アミノフルオレセン、5− カルボキシフルオレセン、6−カルボキシフルオレセン、チオウレアフルオレセ ンおよびメトキシトリアジノリルーアミノフルオレセンから成る群から選択され ることを特徴とする請求項33に記載の標識化試薬。
- (35)下記式: ▲数式、化学式、表等があります▼ の標識化試薬。
- (36)請求項35に記載の標識化試薬のL−異性体。
- (37)下記式: ▲数式、化学式、表等があります▼ [式中、(a)Pは免疫原担体物質であり、(b)Xは結合部分であり、(c) Pのチロキシン誘導体による置換度は1〜100%である。]の免疫原。
- (38)Xが直鎖もしくは分岐鎖、または環式あるいはそれらの組み合わせで配 列した、飽和または不飽和の、0〜50個の炭素原子およびヘテロ原子(ヘテロ 原子は10個以下)から成るが、ただし、1)ヘテロ原子が直接結合するのは2 個までであり、2)Xは−O−O−結合を含むことができず、3)環式部分は6 員環か、それより小さく、4)分岐は炭素原子上にのみあることを特徴とする請 求項37に記載の免疫原。
- (39)免疫原担体物質が牛血清アルブミン、keyholelimpetヘモ シアニンおよびチログロブリンから成る群がら選択されることを特徴とする請求 項37に記載の免疫原。
- (40)下記式: ▲数式、化学式、表等があります▼ [式中、BSAは牛血清アルブミンを示し、BSAのチロキシン誘導体による置 換度は1〜100%である。]の免疫原。
- (41)BSAのチロキシン誘導体による置換度が10〜95%であることを特 徴とする請求項40に記載の免疫原。
- (42)請求項40に記載の免疫原のL−異性体。
- (43)テスト試料中のチロキシンを定量化するためのテストキットであって、 該テストキットが、 (a)下記式: ▲数式、化学式、表等があります▼ [式中、Qは検出可能な部分であり、Wは結合部分である。]の標識化試薬およ び (b)テスト試料中のチロキシンおよび標識化試薬に結合可能な抗体を含む抗体 試薬 を含むことを特徴とするテストキット。
- (44)Wが直鎖もしくは分岐鎖、または環式あるいはそれらの組み合わせで配 列した、飽和または不飽和の、0〜50個の炭素原子およびヘテロ原子(ヘテロ 原子は10個以下)から成るが、ただし、1)ヘテロ原子が直接結合するのは2 個までであり、2)Wは−O−O−結合を含むことができず、3)環式部分は6 員環か、それより小さく、4)分岐は炭素原子上にのみあることを特徴とする請 求項43に記載のテストキット。
- (45)Qが蛍光性部分であることを特徴とする請求項43に記載のテストキッ ト。
- (46)蛍光性部分が、アミノメチルフルオレセン、アミノフルオレセン、5− カルボキシフルオレセン、6−カルボキシフルオレセン、チオウレアフルオレセ ンおよびメトキシトリァジノリルーアミノフルオレセンから成る群から選択され ることを特徴とする請求項45に記載のテストキット。
- (47)抗体が、下記式: ▲数式、化学式、表等があります▼ [式中、(a)Pは免疫原担体物質であり、(b)Xは結合部分であり、(c) Pのチロキシン誘導体による置換度は1〜100%である。]のチロキシン誘導 体から得られる免疫原により産生されることを特徴とする請求項43に記載のテ ストキット。
- (48)Xが直鎖もしくは分岐鎖、または環式あるいはそれらの組み合わせで配 列した、飽和または不飽和の、0〜50個の炭素原子およびヘテロ原子(ヘテロ 原子は10個以下)から成るが、ただし、1)ヘテロ原子が直接結合するのは2 個までであり、2)Xは−O−O−結合を含むことができず、3)環式部分は6 員環か、それより小さく、4)分岐は炭素原子上にのみあることを特徴とする請 求項47に記載のテストキット。
- (49)免疫原担体物質が牛血清アルブミン、keyholelimpetヘモ シアニンおよびチログロブリンから成る群がら選択されることを特徴とする請求 項47に記載のテストキット。
- (50)下記式: ▲数式、化学式、表等があります▼ [式中、Qは検出可能な部分であり、Wは結合部分である。]を有する標識化試 薬であって、該標識化試薬はチロキシンに対する抗体と結合することができるが 、その抗体との結合はL−チロキシンと競合的に置き代わることができ、また、 血清試料の内在性IgGとは結合できない標識化試薬。
- (51)下記式: ▲数式、化学式、表等があります▼ [式中、Pは免疫原担体物質であり、Xは結合部分であり、Pのチロキシン誘導 体による置換度は1〜100%である。]の免疫源の製造性において、該方法が 下記工程:a)L−チロキシンをN−アセチル化してα−N−アセチルーL−チ ロキシンを生成する工程、 b)α−N−アセチル−L−チロキシンを二官能性リンカーと結合させてチロキ シン誘導体を生成する工程、およびc)チロキシン誘導体を免疫原担体物質に結 合する工程を含むことを特徴とする方法。
- (52)下記式: ▲数式、化学式、表等があります▼ [式中、BSAは牛血清アルブミンを示し、牛血清アルブミンのチロキシン誘導 体による置換度は1〜100%である。]の免疫原の製造法において、該方法が 下記工程:a)L−チロキシンをN−アセチル化してα−N−アセチルーL−チ ロキシンを生成する工程、 b)α−N−アセチル−L−チロキシンを6−アミノカブロン酸と結合させてチ ロキシン抱合体を生成する工程、およびc)工程b)のチロキシン抱合体を牛血 清アルブミンに結合する工程 を含むことを特徴とする方法。
- (53)チロキシンを出発物質とする、下記式:▲数式、化学式、表等がありま す▼ [式中、Qは検出可能な部分であり、Wは結合部分である。]の標識化試薬の製 造法において、該方法が下記工程:a)チロキシンのカルボン酸、α−アミノ基 およびフェノール基を個別に保護する工程、および b)チロキシン誘導体のα−アミノ基の保護基を選択的に脱離する工程、および c)チロキシン誘導体のα−アミノ基を選択的にカルボァルコキシメチル化する 工程、次いで、 d)チロキシン誘導体のα−N−カルボキシメチル基およびフェノール基の保護 基を選択的に脱離する工程、次いで、e)チロキシン誘導体のα−N−カルボキ シメチル基を活性化する工程、次いで、 f)チロキシン誘導体の活性化したα−N−カルボキシメチル基を二官能性結合 部分と結合する工程、次いで、g)チロキシン誘導体を検出可能な部分と結合す る工程、ならびに最後に、 h)該標識化試薬のカルボン酸基の保護基を脱離する工程を含むことを特徴とす る方法。
- (54)Wが直鎖もしくは分岐鎖、または環式あるいはそれらの組み合わせで配 列した、飽和または不飽和の、0〜50個の炭素原子およびヘテロ原子(ヘテロ 原子は10個以下)から成るが、ただし、1)ヘテロ原子が直接結合するのは2 個までであり、2)Wは−O−O−結合を含むことができず、3)環式部分は6 員環か、それより小さく、4)分岐は炭素原子上にのみあることを特徴とする請 求項53に記載の方法。
- (55)チロキシンがL−体であることを特徴とする請求項54に記載の方法。
- (56)下記式: ▲数式、化学式、表等があります▼ の標識化試薬の製造法において、該方法が下記工程:(a)(i)チロキシンの ナトリウム塩を塩化9−フルオレニルメトキシカルボニル(FMOC−Cl)と 反応させてアミノ基を保護した後、(ii)得られたチロキシン誘導体のフェノ ール官能基をアセチル化により保護し、次いで(iii)N−FMOC−O−ア セチル−チロキシンのカルボキシル基を保護してt−ブチルエステルとする工程 、 (b)FMOC保護基を脱離してt−ブチル−O−アセチルチロキシンとする工 程、次いで、 (c)t−ブチル−O−アセチル−チロキシンのアミノ基をブロモ酢酸エチルエ ステルでアルキル化してt−ブチル−O−アセチル−N−カルボエトキシメチル チロキシンとする工程、次いで、 (d)t−ブチル−O−アセチル−N−カルボエトキシメチルチロキシンのエチ ルエステル基およびアセチル基を水酸化ナトリウム/メタノールで加水分解し、 同じ工程でt−ブチル N−カルボキシメチル−チロキシンを得る工程、(e) t−ブチル N−カルボキシメチル−チロキシンをジシクロヘキシルカルボジイ ミドおよびN−ヒドロキシスクシンイミドで活性化する工程、次いで、 (f)チロキシン誘導体を5−アミノメチルフルオレセンと反応させてt−ブチ ル N−(5−カルボキサミドメチルフルオレセニルメチル)チロキシンとする 工程、次いで、(g)t−ブチルエステルをトリフルオロ酢酸により加水分解し て標識化試薬を得る工程 を含むことを特徴とする方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/859,775 US5352803A (en) | 1992-03-30 | 1992-03-30 | 5(6)-methyl substituted fluorescein derivatives |
US859,775 | 1992-03-30 | ||
US07/973,140 US5359093A (en) | 1992-03-30 | 1992-11-06 | Reagents and methods for the detection and quantification of thyroxine in fluid samples |
US973,140 | 1992-11-06 | ||
PCT/US1993/002909 WO1993020442A1 (en) | 1992-03-30 | 1993-03-29 | Reagents and methods for the detection and quantification of thyroxine in fluid samples |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07505714A true JPH07505714A (ja) | 1995-06-22 |
JP3327551B2 JP3327551B2 (ja) | 2002-09-24 |
Family
ID=27127537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51759693A Expired - Lifetime JP3327551B2 (ja) | 1992-03-30 | 1993-03-29 | 流体試料中のチロキシンを検出・定量するための試薬および方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US5593896A (ja) |
EP (1) | EP0649533B1 (ja) |
JP (1) | JP3327551B2 (ja) |
CA (1) | CA2131727A1 (ja) |
DE (2) | DE69328622T2 (ja) |
ES (2) | ES2198823T3 (ja) |
HK (1) | HK1026264A1 (ja) |
WO (1) | WO1993020442A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012041303A (ja) * | 2010-08-20 | 2012-03-01 | Fujifilm Corp | チロキシンとアルブミンとの結合体を製造する方法 |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7981420B2 (en) | 2000-12-22 | 2011-07-19 | Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. | Therapeutic use of antibodies directed against repulsive guidance molecule (RGM) |
EP1928905B1 (de) * | 2005-09-30 | 2015-04-15 | AbbVie Deutschland GmbH & Co KG | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
WO2007111851A1 (en) * | 2006-03-24 | 2007-10-04 | Aokin Ag | Use of additives to lower the rate of a binding reaction |
US20080102535A1 (en) * | 2006-11-01 | 2008-05-01 | Chace Donald H | Measuring thyroxine levels from dried blood samples using mass spectrometry |
EP2033971A1 (de) * | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
JP5646457B2 (ja) | 2008-04-29 | 2014-12-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
US20090286329A1 (en) * | 2008-05-19 | 2009-11-19 | Abbott Laboratoires | Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides |
US20090286256A1 (en) * | 2008-05-19 | 2009-11-19 | Abbott Laboratories | Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides |
KR20110016959A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
US8349325B2 (en) | 2008-12-23 | 2013-01-08 | Abbott Laboratories | Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making |
RU2015132478A (ru) | 2009-03-05 | 2015-12-10 | Эббви Инк. | Связывающие il-17 белки |
EP2473852B1 (en) * | 2009-08-31 | 2016-03-30 | Abbott Laboratories | Biomarkers for prediction of major adverse cardiac events and uses thereof |
CN113717286A (zh) * | 2009-12-08 | 2021-11-30 | Abbvie德国有限责任两合公司 | 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体 |
US20110229921A1 (en) | 2010-03-18 | 2011-09-22 | Abbott Laboratories | METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS |
JP5786020B2 (ja) | 2010-04-16 | 2015-09-30 | アボットジャパン株式会社 | 関節リウマチを診断する方法および試薬 |
BR122014011544A2 (pt) | 2010-05-14 | 2019-08-13 | Abbvie Inc | proteínas de ligação à il-1 |
US9551714B2 (en) | 2010-06-25 | 2017-01-24 | Abbott Laboratories | Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies |
WO2012006500A2 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
MY160445A (en) | 2010-08-03 | 2017-03-15 | Abbvie Inc | Dual Variable Domain Immunoglobulins And Uses Thereof |
US20120115244A1 (en) | 2010-11-09 | 2012-05-10 | Abbott Laboratories | Materials and methods for immunoassay of pterins |
BR112013015944A2 (pt) | 2010-12-21 | 2018-06-19 | Abbvie Inc | imunoglobulinas de domínio duplo variável il-1 alpha e beta biespecífico e seus usos. |
CN104203978A (zh) | 2011-10-24 | 2014-12-10 | 艾伯维股份有限公司 | 针对硬化蛋白的免疫结合剂 |
MX2014004980A (es) | 2011-10-24 | 2014-09-11 | Abbvie Inc | Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17. |
EP2791173B1 (en) | 2011-12-14 | 2020-07-29 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
US9636398B2 (en) | 2011-12-14 | 2017-05-02 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
US8993248B2 (en) | 2011-12-31 | 2015-03-31 | Abbott Laboratories | Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use |
LT2807192T (lt) | 2012-01-27 | 2018-07-25 | AbbVie Deutschland GmbH & Co. KG | Kompozicijos ir būdai, skirti ligų, susijusių su neuritų degeneracija, diagnostikai ir gydymui |
KR20140147837A (ko) | 2012-03-13 | 2014-12-30 | 애브비 인코포레이티드 | V1b 길항제 치료요법을 위한 대상체를 선택하거나 선별하는 방법 |
AR091755A1 (es) | 2012-07-12 | 2015-02-25 | Abbvie Inc | Proteinas de union a il-1 |
DE112013006579T5 (de) | 2013-02-02 | 2016-03-10 | Duke University | Verfahren zum Isolieren zirkulierender Tumorzellen |
JP6739329B2 (ja) | 2013-03-14 | 2020-08-12 | アボット・ラボラトリーズAbbott Laboratories | Hcvコア脂質結合ドメインモノクローナル抗体 |
WO2014143342A1 (en) | 2013-03-14 | 2014-09-18 | Abbott Laboratories | Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection |
BR112015023239A8 (pt) | 2013-03-14 | 2018-04-17 | Abbott Lab | ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo |
US9157910B2 (en) | 2013-03-15 | 2015-10-13 | Abbott Laboratories | Assay with increased dynamic range |
US9005901B2 (en) | 2013-03-15 | 2015-04-14 | Abbott Laboratories | Assay with internal calibration |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
WO2015031626A1 (en) | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Soluble cmet assay |
BR112016030008A2 (pt) | 2014-06-27 | 2017-10-24 | Abbott Lab | método para a detecção de infecção por pegivirus humano 2 em um indivíduo, para a detecção de ácido nucleico de pegivirus humano 2 e para a detecção de pegivirus humano 2 em uma amostra, e, composição |
CN104262250A (zh) * | 2014-09-01 | 2015-01-07 | 深圳市美凯特科技有限公司 | 三碘代甲状腺素半抗原发光标记物及合成方法 |
ES2828713T3 (es) | 2014-10-29 | 2021-05-27 | Abbott Lab | Ensayos de detección de anticuerpos anti-VHC objeto usando péptidos de captura NS3 |
BR112017021256A2 (pt) | 2015-04-03 | 2018-06-26 | Abbott Laboratories | dispositivos e métodos para a análise de amostras |
EP3278108B1 (en) | 2015-04-03 | 2021-03-17 | Abbott Laboratories | Devices and methods for sample analysis |
US20170089905A1 (en) | 2015-09-28 | 2017-03-30 | Abbott Japan Co., Ltd. | Methods of diagnosing hepatocellular carcinoma and pancreatic cancer |
AU2017339809B2 (en) | 2016-10-03 | 2022-02-17 | Abbott Laboratories | Improved methods of assessing UCH-L1 status in patient samples |
CN109863396B (zh) | 2016-10-05 | 2021-11-05 | 雅培实验室 | 用于样品分析的装置和方法 |
WO2018175942A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
BR112019021612A2 (pt) | 2017-04-15 | 2020-05-12 | Abbott Laboratories | Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces |
AU2018256845B2 (en) | 2017-04-28 | 2024-03-14 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject |
CN110651190A (zh) | 2017-05-25 | 2020-01-03 | 雅培实验室 | 用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法 |
BR112019025313A2 (pt) | 2017-05-30 | 2020-06-23 | Abbott Laboratories | Métodos para auxílio no diagnóstico e avaliação de uma lesão cerebral traumática leve em um indivíduo humano usando troponina cardíaca i |
JP7454945B2 (ja) | 2017-07-03 | 2024-03-25 | アボット・ラボラトリーズ | 血液中のユビキチンカルボキシ末端ヒドロラーゼl1レベルを測定するための、改善された方法 |
EP3661537A4 (en) | 2017-08-03 | 2021-06-09 | The Cleveland Clinic Foundation | ENHANCED PEPTIDIC EXPRESSION AND DETECTION OF APO-H SPECIFIC SUBJECT ANTIBODIES |
AU2018378971A1 (en) | 2017-12-09 | 2020-01-02 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1) |
WO2019112860A1 (en) | 2017-12-09 | 2019-06-13 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1 |
WO2019133717A1 (en) | 2017-12-29 | 2019-07-04 | Abbott Laboratories | Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury |
US11249091B2 (en) | 2018-02-22 | 2022-02-15 | The Cleveland Clinic Foundation | Detection of glucuronidated and 3-bromotyrosine |
CN112384801A (zh) | 2018-05-04 | 2021-02-19 | 雅培制药有限公司 | 用于改进小体积样品的免疫测定灵敏度和动力学的依次采样方法 |
WO2020180695A1 (en) | 2019-03-01 | 2020-09-10 | Abbott Laboratories | Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease |
CA3175523A1 (en) | 2020-04-13 | 2021-10-21 | Antti Virtanen | Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample |
US20220043000A1 (en) | 2020-08-04 | 2022-02-10 | Abbott Laboratories | Methods and kits for detecting sars-cov-2 protein in a sample |
US20220170948A1 (en) | 2020-12-01 | 2022-06-02 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
WO2022147147A1 (en) | 2020-12-30 | 2022-07-07 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
JP2024517728A (ja) | 2021-04-29 | 2024-04-23 | アボット・ラボラトリーズ | ハイスループット分析用に試料をプールするためのシステム及び方法 |
WO2022245920A1 (en) | 2021-05-18 | 2022-11-24 | Abbott Laboratories | Methods of evaluating brain injury in a pediatric subject |
BR112023026199A2 (pt) | 2021-06-14 | 2024-03-05 | Abbott Lab | Métodos para diagnosticar ou auxiliar no diagnóstico de lesão cerebral causada por energia acústica, energia eletromagnética, onda de sobrepressurização e/ou rajada de vento |
EP4392783A1 (en) | 2021-08-27 | 2024-07-03 | Abbott Laboratories | Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample |
WO2023034777A1 (en) | 2021-08-31 | 2023-03-09 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
WO2023056268A1 (en) | 2021-09-30 | 2023-04-06 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
CA3240822A1 (en) | 2021-12-17 | 2023-06-22 | Tony Lee | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
US20230213536A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
WO2024107430A1 (en) | 2022-11-17 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Methods for assaying enzyme activity |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3714344A (en) * | 1969-05-01 | 1973-01-30 | Mallinckrodt Chemical Works | Method for determining thyroxine in blood serum and reagent therefor |
US4040907A (en) * | 1974-06-20 | 1977-08-09 | Syva Company | Iodothyronine enzyme conjugates |
NL7605447A (nl) * | 1975-06-26 | 1976-12-28 | Byk Mallinckrodt Chem Prod | Radioimmunoproefmethode voor de bepaling van thyroxine. |
US4307071A (en) * | 1977-08-02 | 1981-12-22 | Kallestad Laboratories, Inc. | Analytical reagent and method |
US4329461A (en) * | 1980-01-11 | 1982-05-11 | Syva Company | Fluorescent thyroid hormone conjugates and their uses |
US4391795A (en) * | 1980-03-21 | 1983-07-05 | Becton Dickinson And Company | Assay for free thyroid hormone |
DE3173632D1 (en) * | 1981-09-11 | 1986-03-13 | Amersham Int Plc | Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds |
US4668640A (en) * | 1981-12-11 | 1987-05-26 | Abbott Laboratories | Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins |
US4476229A (en) * | 1982-11-08 | 1984-10-09 | Abbott Laboratories | Substituted carboxyfluoresceins |
US4510251A (en) * | 1982-11-08 | 1985-04-09 | Abbott Laboratories | Fluorescent polarization assay for ligands using aminomethylfluorescein derivatives as tracers |
US4614823A (en) * | 1982-11-08 | 1986-09-30 | Abbott Laboratories | Aminomethylfluorescein derivatives |
US4476228A (en) * | 1982-11-08 | 1984-10-09 | Abbott Laboratories | Determination of unsaturated thyroxine binding protein sites using fluorescence polarization techniques |
US4636478A (en) * | 1984-07-16 | 1987-01-13 | Becton, Dickinson And Company | Monoclonal antibodies recognizing L-thyroxine |
DE3504406A1 (de) * | 1985-02-08 | 1986-08-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur bestimmung der bindungskapazitaet des thyroxin bindenden globulins |
DE3751673T2 (de) * | 1986-10-24 | 1996-08-01 | Abbott Lab | Test, Indikatoren, Immunogene und Antikörper für Benzodiazepine |
US4912208A (en) * | 1987-06-29 | 1990-03-27 | Abbott Laboratories | Fluorophores for encapsulation into liposomes |
US5145790A (en) * | 1990-05-04 | 1992-09-08 | Abbott Laboratories | Reagents and method for detecting polychlorinated biphenyls |
ES2084069T3 (es) * | 1990-08-15 | 1996-05-01 | Abbott Lab | Reactivos de inmunoensayo y metodo para la determinacion de ciclosporina. |
ATE180018T1 (de) * | 1991-08-23 | 1999-05-15 | Molecular Probes Inc | Verwendung von haloalkylderivaten von reportermolekülen zur analyse der metabolischen aktivität in zellen |
US5296599A (en) * | 1991-09-19 | 1994-03-22 | Millipore Corporation | Activated carbamates compounds |
-
1993
- 1993-03-29 EP EP93908638A patent/EP0649533B1/en not_active Expired - Lifetime
- 1993-03-29 DE DE69328622T patent/DE69328622T2/de not_active Expired - Lifetime
- 1993-03-29 JP JP51759693A patent/JP3327551B2/ja not_active Expired - Lifetime
- 1993-03-29 DE DE69332988T patent/DE69332988T2/de not_active Expired - Lifetime
- 1993-03-29 WO PCT/US1993/002909 patent/WO1993020442A1/en active IP Right Grant
- 1993-03-29 ES ES99115138T patent/ES2198823T3/es not_active Expired - Lifetime
- 1993-03-29 ES ES93908638T patent/ES2148225T3/es not_active Expired - Lifetime
- 1993-03-29 CA CA002131727A patent/CA2131727A1/en not_active Abandoned
-
1994
- 1994-07-13 US US08/275,064 patent/US5593896A/en not_active Expired - Lifetime
-
1995
- 1995-05-18 US US08/443,833 patent/US5648272A/en not_active Expired - Lifetime
-
2000
- 2000-05-24 HK HK00103115A patent/HK1026264A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012041303A (ja) * | 2010-08-20 | 2012-03-01 | Fujifilm Corp | チロキシンとアルブミンとの結合体を製造する方法 |
Also Published As
Publication number | Publication date |
---|---|
DE69328622T2 (de) | 2001-02-08 |
JP3327551B2 (ja) | 2002-09-24 |
DE69332988T2 (de) | 2004-05-19 |
HK1026264A1 (en) | 2000-12-08 |
EP0649533A4 (en) | 1996-08-21 |
DE69328622D1 (de) | 2000-06-15 |
EP0649533A1 (en) | 1995-04-26 |
US5648272A (en) | 1997-07-15 |
WO1993020442A1 (en) | 1993-10-14 |
US5593896A (en) | 1997-01-14 |
ES2148225T3 (es) | 2000-10-16 |
CA2131727A1 (en) | 1993-10-14 |
EP0649533B1 (en) | 2000-05-10 |
ES2198823T3 (es) | 2004-02-01 |
DE69332988D1 (de) | 2003-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07505714A (ja) | 流体試料中のチロキシンを検出・定量するための試薬および方法 | |
US5359093A (en) | Reagents and methods for the detection and quantification of thyroxine in fluid samples | |
JPH02300663A (ja) | アンフェタミン様分析対象物の検出のための蛍光偏光イムノアッセイ法およびそれに用いるアッセイキット | |
EP0712497B1 (en) | Reagents and methods for the detection and quantification of testosterone in fluid samples | |
JP3879866B2 (ja) | 生物体液中のバンコマイシンの検出および定量化用試薬および方法 | |
US20070148700A1 (en) | Site-specific aminoglycoside derivatives for use in immunodiagnostic assays | |
Adamczyk et al. | Immunoassay reagents for thyroid testing. 1. Synthesis of thyroxine conjugates | |
AU661013B2 (en) | ddI immunoassays, derivatives, conjugates and antibodies | |
EP0597034B1 (en) | Haptens, tracers, immunogens and antibodies for immunoassays for propoxyphene | |
JPH01143874A (ja) | フェニルアセチルグルタミンの測定のための蛍光偏光イムノアッセイ法 | |
US6175016B1 (en) | Pyridine derivatives | |
JPS59211861A (ja) | オキシトシン測定用酵素標識オキシトシンの製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070712 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080712 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080712 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090712 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090712 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100712 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100712 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110712 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110712 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120712 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130712 Year of fee payment: 11 |